NASDAQ:TIL Instil Bio (TIL) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free TIL Stock Alerts $10.69 -0.35 (-3.17%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$10.58▼$11.0250-Day Range$10.30▼$12.1052-Week Range$6.07▼$12.98Volume5,005 shsAverage Volume10,103 shsMarket Capitalization$69.49 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Instil Bio alerts: Email Address Instil Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside133.9% Upside$25.00 Price TargetShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($6.91) to ($7.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 starsMedical Sector436th out of 928 stocksBiological Products, Except Diagnostic Industry63rd out of 153 stocks 3.3 Analyst's Opinion Consensus RatingInstil Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInstil Bio has only been the subject of 3 research reports in the past 90 days.Read more about Instil Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.53% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently increased by 16.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TIL. Previous Next 3.0 News and Social Media Coverage News SentimentInstil Bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Instil Bio this week, compared to 0 articles on an average week.Search Interest7 people have searched for TIL on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Instil Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Instil Bio are expected to decrease in the coming year, from ($6.91) to ($7.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Instil Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsDon’t buy a single NVIDIA share before you see this...If you feel like NVIDIA is still a good buy - be careful. Billionaires like Steve Cohen, Stanley Druckenmiller and George Soros are ALL dumping NVIDIA... And piling into an overlooked sector...I've prepared a short briefing with all the proof About Instil Bio Stock (NASDAQ:TIL)Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Read More TIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TIL Stock News HeadlinesMay 23, 2024 | markets.businessinsider.comPremier Health Reports 2024 Second Quarter ResultsMay 10, 2024 | investorplace.comTIL Stock Earnings: Instil Bio Misses EPS for Q1 2024May 10, 2024 | markets.businessinsider.comInstil Bio, Inc. Q1 Loss DecreasesMay 10, 2024 | finance.yahoo.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | globenewswire.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 1, 2024 | finance.yahoo.comBiO-LiFE Herbalmeds Launches The Power of Sleep Campaign To Encourage Malaysians To Sleep Well and Stay HealthyApril 21, 2024 | msn.comThis actor once saw father saved murder accused, qualified for Olympics, then became Bollywood's top villain, died at...April 17, 2024 | msn.comInstil Bio (TIL) Price Target Decreased by 23.15% to 28.22April 12, 2024 | msn.comJefferies cuts Instil Bio to hold, cites drug discontinuationMarch 22, 2024 | seekingalpha.comInstil Bio Non-GAAP EPS of -$1.26 beats by $2.14March 21, 2024 | globenewswire.comInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | ft.comA Very Private School — Charles Spencer’s privileged but painful educationMarch 11, 2024 | theguardian.comJon Cruddas: ‘Labour has to rediscover its moral purpose’February 24, 2024 | benzinga.comInstil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and DatesFebruary 21, 2024 | sg.yahoo.comAlexei Navalny death latest: Putin brings new criminal case against critic’s brother as mother pleads for bodyFebruary 19, 2024 | msn.comHow RSS textbooks are reshaping Indian history and science under ModiFebruary 16, 2024 | thestreet.comInstil Bio Inc.February 5, 2024 | msn.comBoeing in ‘last chance saloon’, Emirates boss saysJanuary 17, 2024 | msn.comInstil Bio hits four-month high on rising volumesJanuary 16, 2024 | finance.yahoo.comInstil Bio Announces Strategic UpdateDecember 16, 2023 | msn.comInstil Bio (TIL) Price Target Increased by 1650.00% to 71.40December 13, 2023 | investorplace.comTIL Stock Earnings: Instil Bio Misses EPS for Q3 2023December 13, 2023 | investorplace.comTIL Stock Earnings: Instil Bio Misses EPS for Q1 2023December 5, 2023 | marketwatch.comInstil Bio Shares Fall 7% After Reverse Split NewsDecember 5, 2023 | finance.yahoo.comInstil Bio Announces Effective Date of 1-for-20 Reverse Stock SplitSee More Headlines Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TIL CUSIPN/A CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$32.00 Low Stock Price Target$18.00 Potential Upside/Downside+133.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($18.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.27% Return on Assets-35.73% Debt Debt-to-Equity Ratio0.40 Current Ratio14.19 Quick Ratio14.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$31.65 per share Price / Book0.34Miscellaneous Outstanding Shares6,500,000Free Float3,480,000Market Cap$69.49 million OptionableOptionable Beta1.17 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Bronson Crouch (Age 51)Chairman & CEO Comp: $672.37kDr. Sandeep Laumas M.D. (Age 55)CFO & Chief Business Officer Comp: $489.14kDr. Mark E. Dudley Ph.D.Chief Scientific OfficerDr. Robert Hawkins MBBSPh.D., Head of Research & DevelopmentKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXCentury TherapeuticsNASDAQ:IPSCCaribou BiosciencesNASDAQ:CRBUBlack Diamond TherapeuticsNASDAQ:BDTXAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInstitutional OwnershipAcadian Asset Management LLCSold 3,770 shares on 5/10/2024Ownership: 0.158%BML Capital Management LLCBought 348,735 shares on 4/23/2024Ownership: 5.365%View All Institutional Transactions TIL Stock Analysis - Frequently Asked Questions Should I buy or sell Instil Bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TIL shares. View TIL analyst ratings or view top-rated stocks. What is Instil Bio's stock price target for 2024? 3 Wall Street analysts have issued 1-year price targets for Instil Bio's shares. Their TIL share price targets range from $18.00 to $32.00. On average, they expect the company's share price to reach $25.00 in the next year. This suggests a possible upside of 133.9% from the stock's current price. View analysts price targets for TIL or view top-rated stocks among Wall Street analysts. How have TIL shares performed in 2024? Instil Bio's stock was trading at $7.62 at the beginning of 2024. Since then, TIL shares have increased by 40.3% and is now trading at $10.69. View the best growth stocks for 2024 here. Are investors shorting Instil Bio? Instil Bio saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 8,700 shares, an increase of 16.0% from the April 30th total of 7,500 shares. Based on an average daily volume of 12,200 shares, the short-interest ratio is presently 0.7 days. Currently, 0.5% of the company's shares are sold short. View Instil Bio's Short Interest. When is Instil Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TIL earnings forecast. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) posted its quarterly earnings results on Friday, May, 10th. The company reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.16) by $1.58. When did Instil Bio's stock split? Instil Bio shares reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE). When did Instil Bio IPO? Instil Bio (TIL) raised $250 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO. Who are Instil Bio's major shareholders? Instil Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (5.37%) and Acadian Asset Management LLC (0.16%). View institutional ownership trends. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TIL) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
